| ID | Sequence | Length | GC content |
|---|---|---|---|
| GGACGCAGGUGCCGGCCGGAGCGGAGCUAGUGGCGCCGACGGGCCGGGC… | 1380 nt | 0.6138 | |
| GGACGCAGGUGCCGGCCGGAGCGGAGCUAGUGGCGCCGACGGGCCGGGC… | 1170 nt | 0.6068 | |
| GGACGCAGGUGCCGGCCGGAGCGGAGCUAGUGGCGCCGACGGGCCGGGC… | 2025 nt | 0.6119 | |
| GGACGCAGGUGCCGGCCGGAGCGGAGCUAGUGGCGCCGACGGGCCGGGC… | 1446 nt | 0.6113 | |
| GGACGCAGGUGCCGGCCGGAGCGGAGCUAGUGGCGCCGACGGGCCGGGC… | 1649 nt | 0.6010 | |
| GCUCAGAAGAACAUGUGAGGCCAGGAAGGCUGCUGGCUGAGCUGUUUAG… | 1720 nt | 0.5698 | |
| GGACGCAGGUGCCGGCCGGAGCGGAGCUAGUGGCGCCGACGGGCCGGGC… | 1651 nt | 0.6008 |
MARCH2 is a member of the MARCH family of membrane-bound E3 ubiquitin ligases (EC 6.3.2.19). MARCH enzymes add ubiquitin (see MIM 191339) to target lysines in substrate proteins, thereby signaling their vesicular transport between membrane compartments. MARCH2 reduces surface accumulation of several glycoproteins and appears to regulate early endosome-to-trans-Golgi network (TGN) trafficking (Bartee et al., 2004 [PubMed 14722266]; Nakamura et al., 2005 [PubMed 15689499]).[supplied by OMIM, Mar 2010]
A study in humans demonstrated that the MARCHF2 was downregulated in subcutaneous adipose tissue during short-term weight loss in obese participants [Bollepalli et al. DOI:10.1038/ijo.2017.245].